



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/gpss20>

Synthesis of 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-ones

Sreenu Pavurala^a & Rajeswar rao Vedula^a

^a Department of Chemistry, National Institute of Technology, Warangal, India

Accepted author version posted online: 26 Jul 2013.

To cite this article: Phosphorus, Sulfur, and Silicon and the Related Elements (2013): Synthesis of 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-ones, Phosphorus, Sulfur, and Silicon and the Related Elements, DOI: 10.1080/10426507.2013.798790

To link to this article: <http://dx.doi.org/10.1080/10426507.2013.798790>

Disclaimer: This is a version of an unedited manuscript that has been accepted for publication. As a service to authors and researchers we are providing this version of the accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proof will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to this version also.

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Synthesis of 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-*2H*-chromen-2-ones

Sreenu Pavurala and Rajeswar rao Vedula*


Department of Chemistry, National Institute of Technology, Warangal, India

E-mail: vrasesw@yahoo.com

ABSTRACT

Reaction of coumarin-3-carboxylic acid with 3,5-di mercapto-4-amino-s-triazole in POCl₃ to gave 3-(3-mercapto-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-*2H*-chromen-2-one (**3**). Reaction of **3** with different substituted phenacyl/benzyl/allyl bromides in anhydrous ethanol gave corresponding 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-6-yl)-*2H*-chromen-2-ones **5**. The structures of newly prepared compounds were confirmed from their analytical and spectral data.

Graphical Abstract



Keywords: triazole, 1,3,4-thiadiazol, 1,2,4-triazole, phenacyl bromide, coumarin.

INTRODUCTION

The compounds having sulfur and nitrogen in a 5-membered ring system exhibit broad range of biological properties¹. Thiadiazole and its derivatives have various biological activities such as anti-tuberculosis², anticancer³, carbonicanhydrase-inhibiting effect⁴, antioxidant properties⁵ and antimycobacterial⁶. When thiadiazole is fused with triazoles show antiviral⁷, antitumor⁸, anthelmintic⁹ activities and the substituted triazolo thiadiazoles exhibit various pharmacological activities such as herbicidal¹⁰, anti-HIV-1 effects¹¹. 1,3,4-Thiadiazoles posses various biological activities due to presence of $=\text{N}-\text{C}-\text{S}$ moiety¹².

Coumarins are very important heterocyclic systems used in drugs and dyes¹³. They are usually available from natural sources such as secondary metabolite present in roots and leaves

of many plant species¹⁴. Coumarins and their derivatives show a wide range of biological activities such as HIV protease inhibition¹⁵, anticoagulant¹⁶, anti-inflammatory¹⁷ activity.

Prompted by the above observations and in continuation of our search for biologically active nitrogen and sulfur containing heterocycles¹⁸⁻²⁰, it was decided to synthesize these heterocyclic coumarins.

RESULTS AND DISCUSSION

We have synthesized 3-(3-(phenacyl/alkyl/benzyl thio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2*H*-chromen-2-ones via a two-step process. In the first step, coumarin-3-carboxylic acid (**1**) was reacted with 4-amino-4*H*-[1,2,4]triazole-3,5-dithiol (**2**) in POCl₃. In the second step the intermediate was further reacted with different substituted phenacyl / benzyl/ alkyl bromides (**4**) in anhydrous ethanol under reflux condition for 4-6 h to gave the corresponding thio ethers (**5**). All the thio ethers prepared were new compounds. This is a regioselective S-alkylation. The alkylation of (**3**) with phenacyl/ benzyl/ alkyl bromides may result in different types of products such as N-alkylated, S-alkylated products and a mixture of both. In the present investigation, a mixture of products is not formed (as evidenced by TLC).

The formation of S-alkylated products have been explained in preference to N-alkylated products as due to high nucleophilicity of thiol group²¹. The formation of these S-alkylated products was confirmed by spectral data.

Scheme-1

The compound **3** showed in its IR spectrum characteristic peaks for SH at 2922 cm^{-1} and lactone carbonyl at 1710 cm^{-1} . In the ^1H -NMR (DMSO-d_6) spectrum, the compound **3** showed a characteristic singlet at δ 2.79 for SH and coumarin C-4 proton appeared as singlet at δ 7.25. The remaining aromatic protons were observed in the usual aromatic region. In the mass spectrum the compound **3** exhibited $[\text{M}+\text{H}]^+$ ion at m/z 303.

The compound **5a** was characterized by analytical and spectral data. In the IR spectrum it exhibited a lactonyl carbon band at 1720 cm^{-1} , C=O stretching frequency at 1681 cm^{-1} , C=N stretching frequency at 1610 cm^{-1} respectively.

The ^1H NMR spectrum of **5a** showed -S- CH_2 protons at δ 4.90, aromatic proton chemical shifts appeared in the region δ 7.46-8.04 as a multiplet and the C-4 proton of coumarin resonated at δ 8.97 as a singlet.

The ^{13}C NMR spectrum of **5a** showed carbon chemical shift for - CH_2 - at δ 40.3, the lactone carbonyl carbon resonated at δ 160.8 and carbonyl carbon signal appeared at most downfield δ 192.8. The mass spectrum showed a molecular ion peak at m/z 421.

EXPERIMENTAL

All the reagents and solvents were pure, purchased from commercial sources, and were used without further purification unless otherwise stated. Melting points were determined in open capillaries with a “Cintex” melting point apparatus (Mumbai, India) and were uncorrected. CHN analytical data acquired by Carlo Erba EA 1108 automatic elemental analyzer. The compounds purity was checked by TLC plates (E. Merck, Mumbai, India) . IR spectra (KBr) were recorded on a Bruker WM-4(X) spectrometer (577 model). ^1H NMR spectra were recorded on a Bruker WM-400 spectrometer in δ ppm using TMS as standard. Mass spectra (EI-MS) were determined on Perkin Elmer (SCIEX API- 2000, ESI) at 12.5 eV. The Supplemental Materials contains sample ^1H and ^{13}C NMR spectra for 5a and 5d (Figures S 1 – S 3)

General Procedure for preparation of compound (3)

A mixture of coumarin-3-carboxylic acid **1** (1mmol), 4-amino-4*H*-[1,2,4]triazole-3,5-dithiol **2** (1mmol) and POCl_3 (10 mL) was heated under reflux for 4 h. Excess POCl_3 was removed under reduced pressure. The concentrated mass was cooled and poured into ice to yield a solid product which on washing with NaHCO_3 followed by water and recrystallization from ethanol gave the title compound.

General Procedure for preparation of compounds (5a-j)

A mixture of 3-(3-mercapto-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazol-6-yl)-2*H*-chromen-2-one **3** (1mmol) and appropriate phenacyl/ benzyl/ allyl bromide **4** was refluxed for 4-6 h in

anhydrous ethanol. The reaction mixture was cooled and the solid separated was filtered, washed thoroughly with water and recrystallized from methanol to get the title compounds.

Synthesis of 3-[3-(2-oxo-2-phenyl-ethylsulfanyl)-[1,2,4]triazolo[3,4- b] [1,3,4]thiadiazol-6-yl]-chromen-2-one (5a)

Yellow solid, yield 78%, 4h, m.p. 194-196 °C. IR (KBr, cm^{-1}): ν 1720 (lactone carbonyl carbon of coumarin), 1681 (C=O), 1610 (C=N), 1567 (C=C). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 4.90 (s, 2H, $-\text{SCH}_2\text{CO}-$), 7.46-7.60 (m, 4H, ArH), 7.67 (t, 1H, $J=7.2\text{Hz}$, ArH), 7.82 (t, 1H, $J=7.8\text{Hz}$, ArH), 7.99–8.04 (m, 3H, ArH), 8.97 (s, 1H, C-4 of coumarin). ^{13}C NMR (400 MHz, $\text{DMSO}-d_6$ δ ppm): 40.3, 116.3, 117.0, 118.1, 125.3, 125.6, 128.3, 128.7, 130.7, 133.7, 135.1, 143.4, 150.0, 151.7, 154.3, 158.9, 160.9, 193.1. EI-MS 421 $[\text{M}+\text{H}]^+$. Anal. calcd. For $\text{C}_{20}\text{H}_{12}\text{N}_4\text{O}_3\text{S}_2$: C, 57.13; H, 2.88; N, 13.32; Found: C, 57.10; H, 2.82; N, 13.19.

Synthesis of 3-{3-[2-(4-bromo-phenyl)-2-oxo-ethylsulfanyl]-[1,2,4] triazolo[3,4-b][1,3,4]thiadiazol-6-yl}-chromen-2-one (5b)

Yellow solid, yield 79%, 4h, m.p. 207-209 °C. IR (KBr, cm^{-1}): ν 1722 (lactone carbonyl carbon of coumarin), 1684 (C=O), 1609 (C=N), 1584 (C=C). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 4.85 (s, 2H, $-\text{SCH}_2\text{CO}-$), 7.47-7.61 (m, 2H, ArH), 7.76 (d, 2H, $J=8.4\text{ Hz}$, ArH), 7.82 (t, 1H, $J=7.8\text{ Hz}$, ArH), 7.93 (t, 1H, $J=9\text{ Hz}$, ArH), 8.03 (d, 2H, $J=8\text{ Hz}$, ArH), 8.96 (s, 1H, C-4 of coumarin). ^{13}C NMR (400 MHz, $\text{DMSO}-d_6$ δ ppm): 40.4, 116.2, 116.8, 118.0, 125.2, 127.8, 130.3, 130.7, 131.7, 134.1, 135.1, 150.0, 151.5, 154.3, 158.8, 160.8, 192.4. EI-MS 499 $[\text{M}]^+$.

Anal. calcd. For $C_{20}H_{11}BrN_4O_3S_2$: C, 48.10; H, 2.22; N, 11.22; Found: C, 48.14; H, 2.20; N, 11.18

Synthesis of 3-{3-[2-(4-chloro-phenyl)-2-oxo-ethylsulfanyl]-[1,2,4] triazolo[3,4-b] [1,3,4]thiadiazol-6-yl}-chromen-2-one (5c)

Yellow solid, yield 76%, 4h, m.p. 210-212 °C. IR (KBr, cm^{-1}): ν 1723 (lactone carbonyl carbon of coumarin), 1698 (C=O), 1609 (C=N), 1566 (C=C). 1H NMR (400 MHz, DMSO- d_6): δ 4.86 (s, 2H, -SCH₂CO-), 7.46-7.62 (m, 4H, ArH), 7.82 (t, 1H, J=7.2Hz, ArH), 7.99–8.04 (m, 3H, ArH), 8.96 (s, 1H, C-4 of coumarin). ^{13}C NMR (400 MHz, DMSO- d_6 δ ppm): 40.3, 116.2, 116.8, 118.0, 125.2, 128.8, 130.2, 130.6, 133.8, 135.0, 138.6, 150.0, 151.5, 154.3, 158.8, 160.8, 192.2. EI-MS 455 [M+H]⁺. Anal. calcd. For $C_{20}H_{11}ClN_4O_3S_2$: C, 52.80; H, 2.44; N, 12.32 Found: C, 52.76; H, 2.40; N, 12.28.

Synthesis of 3-(3-(2-(4-nitrophenyl)-2-oxoethylthio)-[1,2,4]triazolo[3,4-b] [1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (5d)

Yellow solid, yield 75%, 5h, m.p. 221-222 °C. IR (KBr, cm^{-1}): ν 1718 (lactone carbonyl carbon of coumarin), 1698 (C=O), 1608 (C=N), 1566 (C=C), 1347 (NO₂). 1H NMR (400 MHz, DMSO- d_6): δ 4.92 (s, 2H, -SCH₂CO-), 7.48-7.56 (m, 2H, ArH), 7.82 (d, 1H, J=7.6Hz, ArH), 8.03 (d, 1H, J=7.6Hz, ArH), 8.22 (d, 2H, J=8.8Hz ArH), 8.35 (d, 2H, J=8.8Hz ArH) 8.96 (s, 1H,

C-4 of coumarin). EI-MS 466 $[M+H]^+$. Anal. calcd. For $C_{20}H_{11}N_5O_5S_2$: C, 51.61; H, 2.38; N, 15.05; Found: C, 51.54; H, 2.35; N, 15.12.

Synthesis of 3-(3-(2-oxo-2-p-tolylethylthio)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-6-yl)- chromen-2-one (5e)

Yellow solid, yield 80%, 4h, m.p. 190-192 °C. IR (KBr, cm^{-1}): ν 1721 (lactone carbonyl carbon of coumarin), 1698 (C=O), 1605 (C=N), 1564(C=C). 1H NMR (400 MHz, DMSO- d_6): δ 2.37 (s, 3H, CH₃), 4.85 (s, 2H, -SCH₂CO-), 7.34 (d, 2H, J=8.0Hz, ArH), 7.46-7.60 (m, 2H, ArH), 7.82–7.93 (m, 3H, ArH), 8.03 (d, 1H, J=8Hz, ArH), 8.96 (s, 1H, C-4 of coumarin). Anal. calcd. For $C_{21}H_{14}N_4O_3S_2$: C, 58.05; H, 3.25; N, 12.89; Found: C, 58.10; H, 3.28; N, 12.85.

Synthesis of 3-(3-(2-(4-methoxyphenyl)-2-oxoethylthio)- [1,2,4]triazolo [3,4-b] [1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (5f)

Yellow solid, yield 84%, 4h, m.p. 205-207 °C. IR (KBr, cm^{-1}): ν 1723 (lactone carbonyl carbon of coumarin), 1676 (C=O), 1598 (C=N), 1564 (C=C). 1H NMR (400 MHz, DMSO- d_6): δ 3.84 (s, 3H, OCH₃), 4.83 (s, 2H, -SCH₂CO-), 7.04-7.06 (d, 2H, J=8.8Hz ArH), 7.46-7.56 (m, 2H, ArH), 7.82 (s, 1H, ArH), 7.96–8.03 (m, 3H, ArH), 8.96 (s, 1H, C-4 of coumarin). Anal. calcd. For $C_{21}H_{14}N_4O_4S_2$: C, 55.99; H, 3.13; N, 12.44; Found: C, 55.91; H, 3.16; N, 12.48.

Synthesis of 3-(3-(2-(biphenyl-4-yl)-2-oxoethylthio)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-6-yl)-2H-chromen-2-one (5g)

Yellow solid, yield 75%, 5h, m.p. 207-209 °C. IR (KBr, cm⁻¹): ν 1722 (lactone carbonyl carbon of coumarin), 1697 (C=O), 1603 (C=N), 1565 (C=C). ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.92 (s, 2H, -SCH₂CO-), 7.44-7.55 (m, 5H, ArH), 7.75 (d, 2H, J= 8 Hz, ArH), 7.83 (t, 3H, J= 8.6 Hz, ArH), 8.02 (d, 1H, J= 8 Hz, ArH), 8.08 (d, 2H, J= 8.4 Hz, ArH), 8.99 (s, 1H, C-4 of coumarin). ¹³C NMR (400 MHz, DMSO-*d*₆ δ ppm): 40.4, 116.2, 116.9, 118.0, 125.2, 126.8, 126.9, 128.4, 129.0, 129.1, 130.6, 133.9, 135.0, 138.6, 150.0, 151.6, 154.3, 158.9, 160.8, 192.7. Anal. calcd. For C₂₆H₁₆N₄O₃S₂: C, 62.89; H, 3.25; N, 11.28; Found: C, 62.77; H, 3.28; N, 11.24.

Synthesis of 3-(3-(benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (5h)

Red solid, yield 73%, 5h, m.p. 225-227 °C. IR (KBr, cm⁻¹): ν 1705 (lactone carbonyl carbon of coumarin), 1603 (C=N), 1562 (C=C). ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.50 (s, 2H, -SCH₂-), 7.22-7.33 (m, 5H, ArH), 7.53 (d, 1H, J=7.6Hz, ArH), 7.60 (d, 1H J=8.4Hz, ArH), 7.82 (d, 1H, J=7.2Hz, ArH), 8.14 (d, 1H, J=8.0Hz ArH), 9.13 (s, 1H, C-4 of coumarin). Anal. calcd. For C₁₉H₁₂N₄O₂S₂: C, 58.15; H, 3.08; N, 14.28; Found: C, 58.18; H, 3.12; N, 14.32.

Synthesis of 3-(3-(3-nitrobenzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (5i)

Red solid, yield 70%, 6h, m.p. 232-234 °C. IR (KBr, cm⁻¹): ν 1708(lactone carbonyl carbon of coumarin), 1606 (C=N), 1563 (C=C), 1344 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆): δ

4.46 (s, 2H, -SCH₂-), 7.53-7.64 (m, 4H, ArH), 7.82 (s, 1H, ArH), 8.02 (d, 1H, J=6.0Hz ArH), 8.12-8.17 (m, 2H, ArH), 9.09 (s, 1H, C-4 of coumarin). Anal. calcd. For C₁₉H₁₁N₅O₄S₂: C, 52.17; H, 2.53; N, 16.01; Found: C, 52.14; H, 2.58; N, 16.12.

Synthesis of 3-(3-(allylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-one (5j)

Red solid, yield 72%, 6h, m.p. >300 °C. IR (KBr, cm⁻¹): ν 1708 (lactone carbonyl carbon of coumarin), 1605 (C=N), 1562 (C=C). ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.92 (d, 2H, J=7.2 Hz, -SCH₂-), 5.13 (d, 1H, J=8.8 Hz, CH₂ of allyl proton), 5.23 (d, 1H, J= 8 Hz, CH₂ of allyl proton), 5.99 (m, 1H, CH of allyl proton), 7.99-8.04 (m, 4H, ArH), 8.64 (s, 1H, C-4 of coumarin). EI-MS 343 [M+H]⁺. Anal. calcd. For C₁₅H₁₀N₄O₂S₂: C, 52.62; H, 2.94; N, 16.36; Found: C, 52.58; H, 2.92; N, 16.31.

CONCLUSION

In conclusion we have developed an efficient regioselective approach for the synthesis of 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-ones in a simple procedure. The yields of the products are good in this synthesis.


ACKNOWLEDGEMENT

We are thankful to CSIR-New Delhi for providing the financial assistance and to the Director of NIT-Warangal for research facilities.

REFERENCES

1. (a) Cantello, B. C. C. *J. Med. Chem.* **1994**, 37, 3977-3985.
 (b) Schneider, C. S.; & Mierau, J. *J. Med. Chem.* **1987**, 30, 494-498.
 (c) Anden, N. E.; & Grabovaska, M. *J. Neutral Transm.* **1990**, 79(3), 209.
 (d) Lewis S, US patent 3017415, **1962**.
2. Karakus, S.; Rollas, S. *Farmaco.* **2002**, 57, 577-581.
3. Terzioglu, N.; Gursoy, A. *Eur. J. Med. Chem.* **2003**, 38, 781-786.
4. Nadeem, S.; Priya, A.; Waquar, A.; Pandeya, S.; and Shamsheer, M. *J. Chem. Pharm. Res.* **2009**, 1(1), 19-30.
5. Martinez, A.; Alonso, D.; Castro, A.; Aran, V. J.; Cardelus, I.; Banos, J. *Arch. Pharm.* **1999**, 332, 191-194.
6. Oruc, E. E.; Rollas, S.; Kandemirli, F.; Shvets, N.; and Dimoglo, A. *J. Med. Chem.* **2004**, 47, 6760-6767.
7. Invidiata, F. P.; Simoni, D.; Scintu, F.; Pinna, N. *Farmaco.* **1996**, 51, 659-664.
8. Al-Masoudi, N. A.; Al-Soud, Y. A. *Nucleosides Nucleotides Nucleic Acids*, **2008**, 27, 1034-1044.
9. El Khawass, S. M.; Khalli, M. A.; Hazza, A. A.; Bassiouny, A.; Loutfy, N. F. *Farmaco.* **1989**, 44, 703-709.
10. Nizamuddin, Gupta, M.; Khan, M. H.; and Srivastava, M. K. *J. Sci. Ind. Res.* 1999, 58, 538-542
11. Invidiata, F. P.; Simoni, D.; Scintu, F.; Pinna, N. *Farmaco.* **1996**, 51, 659-664

12. Holla, B. S.; Poorjary, K. N.; Rao, B. S.; Shivananda, M. K. *Eur. J. Med. Chem.* **2002**, 37, 511-517.
13. Rajasekaran, S.; Rao, G. K; Pai, S. P. N; Ranjan, A. *Int. J. Chem. Tech. Res.* **2011**, 3(2), 555-559.
14. More, D. H.; Mahulikar, P. P. *Indian J. Chem.*, **2011**, 50(B), 745-747.
15. Bourinbaiar A. S.; Tan, X.; Nagomy, R.; *Acta Virol.* **1993**, 37, 241-250 and Tummino, P. J.; Ferguson, D.; Hupe, D.; *Biochem. Biophys. Res. Commun.* **1994**, 201, 290-94.
16. Manolov, I.; and Danchev, N. D. *Eur. J. Med. Chem. Chim. Ther.* **1995**, 30(6), 531-536.
17. Emmanuel-Giota, A. A.; Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.; and, Nicolaides, D.N. *J. Heterocycl. Chem.* **2001**, 38(3), 717-722.
18. Vijayakumar, P.; Rajeswar Rao, V. *Indian J. Chem.*, **2008**, 47, 106-111.
19. Srimanth, K.; Rajeswar Rao, V.; and Krishna D. R. *Arzneim.-Forsch.* **2002**, 52(5) ,388-392.
20. Srinivas, V.; Rajeswar Rao, V. *J. Sulfur Chem.* **2011**, 32, 99-104.
21. Rajeswar Rao, V.; Srimanth, K.; and Vijaykumar, P. *Indian J. Heterocycl. Chem.* **2004**, 14, 141-144.



	R_1		R_1
5a	Phenacyl	5f	p-Methoxy phenacyl
5b	p-Bromo phenacyl	5g	p-Phenyl phenacyl
5c	p-Chloro phenacyl	5h	Benzyl
5d	p-Nitro phenacyl	5i	m-Nitro benzyl
5e	p-Methyl phenacyl	5j	Allyl

Scheme-1: Synthesis of 3-(3-(phenacyl/alkyl/benzylthio)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-2*H*-chromen-2-ones

Supplemental Materials




Figure S 1: ^{13}C NMR of 5a




Figure S 2: ^1H NMR of 5a




Figure S 3: ^1H NMR of 5d